The adeno-associated virus-mediated HSV-TK/GCV suicide system: a potential strategy for the treatment of bladder carcinoma.
Novel treatment strategies such as gene therapy are warranted in view of the failure of current treatment approaches to cure a high percentage of patients with advanced bladder cancers. The emergence of cancer gene therapy potentially offers a number of exciting treatments. The majority of approaches involve strategies to suppress the function of activated oncogenes to restore the expression of functional tumour suppressor genes or to initiate tumour self-destruction. One gene therapy approach against tumours that holds great promise is suicide gene therapy. Herpes simplex virus thymidine kinase (HSV-TK) phosphorylates ganciclovir (GCV), which in turn interacts with cellular DNA polymerase and interferes with DNA synthesis to cause death of rapidly dividing cells. The development of an effective delivery system is absolutely critical to the usefulness and safety of gene therapy. At present, the adeno-associated virus (AAV) vector has the most promising potential in view of its non-pathogenicity, wide tropisms and long-term transgene expression in vivo. Gene therapy studies using different serotypes of recombinant AAV (rAAV) as delivery vehicles have proved rAAVs to be an effective modality of cancer gene therapy. In the present study, we investigated the suppression effect of AAV-mediated HSV-TK/GCV system on the bladder cancer cells and in mice xenograft models of bladder cancer. Our data demonstrate that rAAV-HSV-TK system controlled tumour cell growth and achieves strong antitumour efficacy in vivo. These findings provide a foundation for the development of potential targeted clinical therapies for bladder cancer in humans.
The Second Affiliated Hospital of Guangzhou Medical University, Changgang Dong Lu, No 250, Guangzhou 510260, China. thatdaypjg@163.com
Jian Gang
JG
Pan
Xing
X
Zhou
Runqi
R
Luo
Rui Fa
RF
Han
D000818:Animals; D000229:Dependovirus; D016503:Drug Delivery Systems / Q000379:methods*; D015774:Ganciclovir / Q000008:administration & dosage*; D041722:Genes, Transgenic, Suicide / Q000502:physiology*; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D018139:Simplexvirus / Q000502:physiology; D013937:Thymidine Kinase / Q000378:metabolism; D001749:Urinary Bladder Neoplasms / Q000628:therapy*; D014764:Viral Proteins / Q000378:metabolism; D023041:Xenograft Model Antitumor Assays
D014764:Viral Proteins; D013937:Thymidine Kinase; D015774:Ganciclovir